The video recording of the event can be found here. Tuesday June 23, 2020
The video recording of the event can be found here.
Tuesday June 23, 2020
09:00 – 09:30 am (San Francisco)
12:00 – 12:30 pm (Boston/New York)
19:00 – 19:30 (Greece/Cyprus)
Hellenic Innovation Network, with the support of the Greek Consulate of Boston and MIT Enterprise Forum Greece, hosts events to educate those in the US about technology innovation and entrepreneurship in Greece, and offer Greek entrepreneurs an opportunity to pitch and network in the US. While our events are typically held in Boston, due to the covid-19 situation we are hosting a series of webcasts in order to keep our community connected until our next in-person event.
Speaker: Manolis Kellis, Ph.D., Professor, Computer Science, MIT
Manolis Kellis , Ph.D., is Professor of Computer Science at MIT, a member of the Broad Institute of MIT and Harvard, a Principal Investigator of the Computer Science and Artificial Intelligence Lab at MIT, and the Head of the MIT Computational Biology Group (compbio.mit.edu). His research is dissecting the mechanisms underlying human disease, using genetics, genomics, epigenomics, gene regulation, and high-throughput experiments, with broad implications for medicine and human health
Professor Kellis’ work is revolutionizing our understanding of the human genome and human disease, across Alzheimer’s, obesity, schizophrenia, heart disorders, and cancer. He has developed and disseminated some of the most widely-used techniques and resources in genomics. He has more than 220 publications with more than 90,000 citations, and has received multiple scientific awards, including the US Presidential Early Career Award (PECASE) by President Barack Obama. He has led several large-scale genomics projects, including the Roadmap Epigenomics project, the ENCODE project, the Genotype Tissue-Expression (GTEx) project, and comparative genomics projects in mammals, flies, and yeasts. He lived in Greece and France before moving to the US, and he has studied and conducted research at MIT, the Xerox Palo Alto Research Center, and the Cold Spring Harbor Lab.
|Moderator: Katia Catherine Karalis, MD, PhD, Executive Director for Biology, RGC, Regeneron, Inc.
Dr. Karalis is trained in genetics and experimental endocrinology with broad experience and contributions in basic and translational research as well as strategic, scientific and managerial leadership of multidisciplinary teams in academic and industry settings. The focus of her interest is in the understanding how distrurbed homeostasis of the organism such as when exposed to external or internal challneges, drives disease mechanisms and how we can overcome the insults with new therapeutics.She has solid experience in inflammatory diseases, immune response, stress responses, metabolism, organoids, and organ chip technology.
At Emulate based on their Organs-on-Chips technology platform, as the EVP of Research she has been leading the team to develop disease models in micro-engineered environments and accurately understand how different diseases, medicines, chemicals and foods affect us and elucidate mechanisms driving the spectrum of individual’ responses. Models developed by the team are commercialized by Emulate and employed by a number of academic and industry groups around the world. Prior to joining Emulate she was heading the Developmental Biology Section at the Biomedical Research Foundation of the Academy of Athens, working on experimental models of human diseases with focus on intestinal inflamation, metabolism and tissue regeneration. She is affiliated faculty at the BSRC Alexander Fleming in Greece and Harvard Medical School, where she was Assistant Professor of Pediatrics and faculty at the Division of Endocrinology of Children’s Hospital. She has been a Helmholtz International fellow and a Visiting Scholar at Wyss Institute Harvard Medical School.
She joins the Regeneron Genetics Center to lead the Biology group for the understanding of new mechanisms for genetic inflammatory, metabolic and neurodegenerative diseases and development of new drugs for human patients.
(Tuesday) 12:00 pm - 12:45 pm